Latest news with #SebastianKahnert
The Star
03-08-2025
- Health
- The Star
Patients have less trust in doctors who use AI, study shows
When doctors work with artificial intelligence, their patients consider them less competent, empathetic and trustworthy, new research suggests. — Photo: Sebastian Kahnert/dpa BERLIN: Doctors who work with artificial intelligence (AI) are rated less favourably by patients, according to psychologists from the University of Würzburg and Charité Berlin. A study they conducted found that doctors who state they use AI in their work are perceived as less competent, trustworthy, and empathetic. These reservations were evident even when AI was not used for diagnostic or therapeutic purposes but only for administrative tasks. The information was obtained after 1,276 adult participants from the United States were shown advertisements for medical practices and asked to evaluate various characteristics of the doctors depicted, according to the study published in the scientific journal JAMA Network Open. The advertisements differed in only one aspect, according to the psychologists: a statement indicating that the doctor used AI for administrative, diagnostic or therapeutic purposes. A control group was shown the same advertisement without any mention of AI. Why do patients apparently have a negative perception of doctors who work with AI? The authors of the study, Moritz Reis and Professor Wilfried Kunde from Würzburg and Florian Reis from the Institute of Medical Informatics at Charité Berlin, suspect one reason could be the fear that doctors might blindly follow AI recommendations. As in many other fields, AI is playing an increasingly significant role in modern medicine. However, the researchers noted that a trusting relationship between patient and doctor is crucial for successful treatment. "When doctors inform their patients about the use of AI, they should aim to address potential concerns and highlight possible benefits," the authors summarised in a statement from the Julius Maximilian University. Doctors, for instance, could have more time for their patients if part of the administrative workload is handled by AI. "Despite increasing technologisation, AI could even make our healthcare system more humane in this way," they said. – dpa
Forbes
29-07-2025
- Automotive
- Forbes
What's Driving American Battery Tech Stock Up 2x In A Month?
09 July 2025, Saxony, Kamenz: Employees of the Mercedes subsidiary Accumotive are working on a ... More production line for battery systems for electric cars. The plant is now producing lithium-ion batteries for the Mercedes-Benz CLA. Photo: Sebastian Kahnert/dpa (Photo by Sebastian Kahnert/picture alliance via Getty Images) American Battery Technology (NASDAQ:ABAT) has experienced a stock increase of over 100% in the last month, rising from approximately $1.35 to more than $3 per share. What factors are behind this rise, and is there potential for further growth? Lithium Mining Push The recent increase seems to be linked to the rising support for ABAT's Tonopah Flats Lithium Project (TFLP) in Nevada, which received "FAST-41" transparency priority status from the U.S. Federal Permitting Council. This classification aids in expediting federal approvals from various agencies and signals the project's strategic significance. The initiative is ambitious, aiming to create a domestic lithium mine and a refinery capable of producing 30,000 metric tons of lithium hydroxide each year – a crucial component for electric vehicle (EV) batteries and energy storage systems. ABAT has also obtained notable financial support, including a $58 million grant from the U.S. Department of Energy and a $900 million letter of interest from the Export-Import Bank of the United States to facilitate project construction and expansion. Battery Recycling Gains Importance As the U.S. takes steps to lessen its dependence on Chinese critical mineral imports, ABAT's domestic emphasis – in both mining and its closed-loop battery recycling facility – aligns perfectly with these policy developments. The company's commercial-scale recycling facility in Nevada allows it to reclaim battery-grade lithium and other essential metals from used batteries, thus fostering a more sustainable domestic supply chain. The company focuses on the extraction, refinement, and recycling of essential battery materials such as lithium and cobalt – critical elements for electric vehicles (EVs) and clean energy storage systems, by methodically disassembling battery packs instead of shredding or smelting. This system accommodates various lithium-ion battery chemistries and forms. Although the business is relatively small at present, battery recycling has the potential to evolve into a significant industry in the long term, particularly as the EV sector matures and the demand for EV upgrades increases. More Gains For the Stock? That being said, the stock remains highly speculative. Even with the potential for growth driven by increasing lithium demand and EV adoption, ABAT is still in the nascent stages of commercialization. Over the last 12 months, the company generated only $1.9 million in revenue while experiencing an operating loss of $46 million. Its price-to-sales ratio is an exorbitant 144.5, significantly higher than the S&P 500 average of 3.1, and its market capitalization is below $300 million. Though government backing and its significance to the clean energy shift provide strong incentives, ABAT is still a small-cap, early-stage firm vulnerable to operational, financial, and execution challenges common in such undertakings. While it's wise to exercise caution regarding ABAT stock at the moment, you might consider looking into the Trefis Reinforced Value (RV) Portfolio, which has surpassed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) yielding strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks has provided an agile approach to capitalize on favorable market conditions while minimizing losses during downturns, as outlined in RV Portfolio performance metrics.
Newsweek
25-04-2025
- Health
- Newsweek
Juice Recall Update As FDA Issues Highest Risk Warning for 12 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Juice recalled over potential harmful bacteria contamination has been issued a Class I risk warning by the Food and Drug Administration (FDA). Walker's Wine Juice LLC of Forestville, New York, recalled its pumpkin juice on March 28 due to possible contamination with Clostridium botulinum, a bacterium that can cause botulism, a serious illness that affects the nervous system. The product was distributed in 12 states, including Illinois, Indiana, Kansas, Kentucky, Maine, Michigan, Minnesota, New Jersey, New York, Ohio, Pennsylvania and Wisconsin. Newsweek has contacted Walker's Wine Juice for comment. Walker's Wine Juice LLC recalled its pumpkin juice on March 28 due to possible contamination with Clostridium botulinum. Walker's Wine Juice LLC recalled its pumpkin juice on March 28 due to possible contamination with Clostridium botulinum. Andreas Franke/Sebastian Kahnert/DPA/AP Why It Matters Botulism, a potentially fatal form of food poisoning caused by Clostridium botulinum, can cause a wide range of symptoms including general weakness, dizziness, double-vision and trouble with speaking or swallowing. It can also cause difficulty in breathing, weakness of other muscles, abdominal distension and constipation. According to the FDA, around 10 outbreaks of foodborne botulism occur annually in the U.S. What To Know The affected products were packaged in 2.5- and 5-gallon boxes, along with 30-, 60- and 275-gallon bulk containers. All lots and codes of the product were included in the recall, and the FDA said that a total of 1,466 gallons of juice were affected. According to the FDA, the recall is still ongoing. As of April 1, no illnesses had been reported, Walker's Wine Juice said. The FDA issued its Class I risk classification on April 222, meaning it is a "situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." The potential contamination was discovered after inspectors from New York's Department of Agriculture and Markets found that the pumpkin juice pH was too high for the "hot fill" process to be carried out effectively when being packaged. The FDA said that is was subsequently determined that "no adequate kill step was used to address the possibility of microbiological hazards." What People Are Saying The World Health Organization said on its website about botulism: "Foodborne botulism is a serious, potentially fatal disease. However, it is relatively rare. It is an intoxication usually caused by ingestion of potent neurotoxins, the botulinum toxins, formed in contaminated foods. Person to person transmission of botulism does not occur." The FDA wrote in a report on the bacteria: "A food may contain viable C. botulinum and still not be capable of causing botulism. If the organisms do not grow, no toxin is produced. Although many foods satisfy the nutritional requirements for the growth of C. botulinum, not all of them provide the necessary anaerobic conditions. Both nutritional and anaerobic requirements are supplied by many canned foods and by various meat and fish products. Refrigeration will not prevent growth and toxin formation by nonproteolytic strains unless the temperature is precisely controlled and kept below 3°C. Foods processed to prevent spoilage but not usually refrigerated are the most common vehicles of botulism." What Happens Next Walker's Wine Juice LLC has warned any consumers experiencing symptoms related to botulism to seek immediate medical attention.
